TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Post Traumatic Stress Disorder Checklist - Civilian (PCLC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Graded Chronic Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Health Questionnaire - 9 (PHQ 9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to occurrence of a major cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Linkage to HIV Care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative aspect and position of the gonial angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of renal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Completion of 4 ACP behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants With and Severity of Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed Prostate Specific Antigen (PSA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in aqueous humor flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in outflow facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in episcleral venous pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of Participants With Treatment-emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With New Onset Chronic Diseases (NOCDs)
Endpoint domain: Adverse events/effects
Primary endpoint: Jaw Functional Limitation Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Anti-mullerian hormone (AMH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Targeted fruit and vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Raynaud attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of TB disease recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Insomnia Severity Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in quality of life at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in quality of life at 24 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Geographic atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Retinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical and medullary renal R2* MRI signal variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection of erythrocytic stage P. vivax parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence and intensity of solicited and unsolicited symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Solicited Subjective Local Reactions After First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With 4-fold or Greater Serum Hemagglutination Inhibition (HAI) Antibody Titer Increases Against Influenza H1N1 2009 Virus Following a Single Dose of H1N1 Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gustatory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of tubal ligation
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of radioactive dose of [14C] radiolabelled SH-1028 recovered in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of radioactive dose of [14C] radiolabelled SH-1028 recovered in urine, faeces and in total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Types of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: diversity of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in detection of posterior vitreous detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment effect by radiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Relapse or Progression
Endpoint domain: Mortality/survival
Primary endpoint: Change in postprandial plasma endotoxemia binding protein kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IP-10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Achieving PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of choroidal neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of the Combination Carboplatin plus Celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Maximum Tolerated Dose of Intraperitoneal Autologous Monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Maximum Tolerated Dose of Sylatron (Peginterferon Alpha-2b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Maximum Tolerated Dose of Actimmune (Interferon Gamma-1b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSFI SCORE difference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distance walked (machine-reported)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assisted primary and secondary patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: proportion of responders with hair re-growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin 4 and Interleukin 10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Coefficient of variation for area of RPE elevation measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient adherence to anti-retroviral therapy (ART)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention to care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ongoing safety of Genentech GH preparations
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Genentech GH preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Single Oral Doses
Endpoint domain: Adverse events/effects
Primary endpoint: Qolie-10 scores between groups
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Body image scores between groups
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of days of abstinence before relapse
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Subjects Transfused at Least 1 Unit of Packed Red Blood Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Area Under the Plasma Glucose Concentration Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chronic pain at or near the surgical site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients with improvement in INCAT disability scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of tissue fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Urinary Free Cortisol (UFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mechanical ventilation requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Flu Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of people recovering from COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Functioning scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Subsidence of CMC joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hip adductor and spin muscles electromyography (EMG) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: GSH and GSSG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Change of noradrenalin plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of thrombin formation and fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Vomiting/Retching
Endpoint domain: Adverse events/effects
Primary endpoint: Change in likelihood of undergoing male circumcision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subsequent pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3D 13C lactate images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tolerability of SECM Capsule Imaging Procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in VDR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and intensity of nausea and vomiting episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients with postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of the treatment related pain
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of the adverse effect of 1540nm fractional laser versus untreated control site
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients with loss of > 5% body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Medication Integration Protocol Feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Households with New SARS-CoV-2 Infection by Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) from time zero to the last sampling time (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death/myocardial infarction/stroke/emergency hospitalization for acute coronary syndrome/hospitalization for congestive heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy based on standard response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline Lens Power vs Post dilation measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary pharmacokinetic parameter for S-enantiomer of ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in sub-maximal exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of mild cognitive impairment or dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Average Numerical Rating Scale (NRS) Score at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: IABP insertion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of serious device related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change of AHI (Apnea-Hypopnea Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Identification of the rotator cable and associated structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Perth Hamstring Assessment Tool (PHAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee flexion strength of affected leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip extension strength of affected leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readiness to change alcohol and other drug use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Readiness to change risky sexual behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self efficacy to change alcohol and other drug use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of In-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Abdominal Distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline diagnosis based on DSM-5 criteria to immediately after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline depression symptoms to immediately after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline parent-reported anxiety symptoms to immediately after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Sperm motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Achievement of Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oculocardiac reflex rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ALS Functional Rating Scale - Revised (ALSFRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the average daily pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge Levels of Pregnant Women Regarding Oral and Dental Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral and Dental Health Behaviors of Pregnant Women
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pregnant Women's Education Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of JSP191
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of JSP191
Endpoint domain: Physiological/clinical
Primary endpoint: Inpatient Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Interleukin-6 (IL-6) plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnosis of malignant disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Obturation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filling quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BI-AAQ Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Patients Admitted to ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of Intraoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Injection-site Reactions Post Tdap and IIV4 Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Systemic Reactions Post Tdap and IIV4 Administration - Visit 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Seroprotection as Determined by Diphtheria Serum Antibody Levels (Defined as ≥ 0.1 IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to closure of a Diabetic Foot Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for hemodynamically significant coronary artery stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Patients Who Attained MBE at the TOC Visit in the Microbiologically Evaluable (ME) Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Patients With Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-HBs antibody geometric mean concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With ACR20 Response at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 52 in mTSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 24 in HAQ-DI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Toxicity assessed by CTCAE criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change From Baseline in Severity of Alopecia Tool I (SALT I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversation with a communication partner
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: anatomical feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Disinhibited eating behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: readmission rate due to respiratory infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: duration of the hospital stay due to respiratory infection
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Acceptability and demand of the e-Health intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the trial procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adaptation of the e-Health intervention and trial procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change of Cobb angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cheating rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: degree of control of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Treatment Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of SARS CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Th1 immune response measured by cytokine expression (IFN gamma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of the addition of vancomycin to Stereotactic Body Radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the addition of vancomycin to precision hypofractionated radiation
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the Visual Analogue Scale for Craving (VAS-craving)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Pathological Gambling Adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Gambling Disorder Severity as assessed by Timeline Follow Back (TLFB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Gambling Behavior as assessed by Gambling Symptom Assessment Scale (G-SAS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological recurrence of HBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of Total Score of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spanboard task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AVLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Go No-go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of wound management complications
Endpoint domain: Adverse events/effects